Back to Rankings

HCAT

Health CatalystC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-18
View Chart
Documents
61
Stored
Transcripts
1
Recent loaded
Latest report
2026-05-20
Investor release

Document history

Earnings documents stored for HCAT.

12 shown
Investor releaseQuarter not tagged2026-05-20

5 Insightful Analyst Questions From Health Catalyst’s Q1 Earnings Call

StockStory

Health Catalyst’s first quarter results were shaped by ongoing efforts to streamline its operations and address challenges from its previous client migration strategy, with management highlighting that a rigid migration timeline led to client churn and revenue pressure. CEO Benjamin Albert noted, “Setting a rigid timeline for migration efforts over the last 2 years has created a churn dynamic.” Despite these headwinds, the company reported strong bookings and progress on cost-saving initiatives, which contributed to a positive market reaction. Is now the time to buy HCAT? Find out in our full research report (it’s free). Revenue: $70.76 million vs analyst estimates of $69.19 million (10.9% year-on-year decline, 2.3% beat) Adjusted EPS: $0.02 vs analyst estimates of $0.01 (in line) Adjusted Operating Income: -$2.98 million vs analyst estimates of -$10.81 million (-4.2% margin, 72.4% beat) Revenue Guidance for the full year is $262.5 million at the midpoint, below analyst estimates of $278.9 million EBITDA guidance for the full year is $31.5 million at the midpoint, below analyst estimates of $34.2 million Operating Margin: -150%, down from -25.4% in the same quarter last year Billings: $84.21 million at quarter end, down 11.7% year on year Market Capitalization: $87.93 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Stanislav Berenshteyn (Wells Fargo) asked about the shrinking services mix. CEO Benjamin Albert explained services will decline as a percentage of revenue, but value-added services like chart abstraction will remain, often enhanced by AI. Richard Close (Canaccord Genuity) questioned client hesitancy to migrate from DAS to Ignite. Albert clarified that clients derive significant value from DAS and that transitions require substantial effort, so the company is now meeting clients where they are, rather than imposing rigid migration timelines. Jeffrey Garro (Stephens) inquired about customer feedback on Ignite Intelligence and AI budgeting. Management reported strong early feedback, citing the unique value of its proprietary improvement data and positive reception to cost management AI applications....

Investor releaseQuarter not tagged2026-05-13

Health Catalyst (HCAT) Reports Q1: Everything You Need To Know Ahead Of Earnings

StockStory

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) will be reporting results this Monday after market hours. Here’s what you need to know. Health Catalyst beat analysts’ revenue expectations last quarter, reporting revenues of $74.68 million, down 6.2% year on year. It was a slower quarter for the company, with revenue guidance for next quarter missing analysts’ expectations significantly and EBITDA guidance for next quarter missing analysts’ expectations significantly. Is Health Catalyst a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Health Catalyst’s revenue to decline 12.9% year on year, a reversal from the 6.3% increase it recorded in the same quarter last year. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Health Catalyst rarely misses Wall Street’s revenue estimates. Looking at Health Catalyst’s peers in the data analytics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Palantir Technologies delivered year-on-year revenue growth of 84.7%, beating analysts’ expectations by 6.1%, and CLEAR Secure reported revenues up 19.7%, topping estimates by 3.5%. Palantir Technologies traded down 6.9% following the results while CLEAR Secure was also down 1.2%. Read our full analysis of Palantir Technologies’s results here and CLEAR Secure’s results here. There has been positive sentiment among investors in the data analytics segment, with share prices up 26.5% on average over the last month. Health Catalyst is up 49.6% during the same time and is heading into earnings with an average analyst price target of $1.79 (compared to the current share price of $1.52). ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Investor releaseQuarter not tagged2026-05-12

Health Catalyst Q1 Earnings Call Highlights

MarketBeat

Interested in Health Catalyst, Inc.? Here are five stocks we like better. Health Catalyst beat Q1 expectations, reporting revenue of $70.8 million and adjusted EBITDA of $9.1 million, both above guidance. The company also ended the quarter with $108.8 million in cash and investments. Project Nexus is a major restructuring effort aimed at simplifying operations and cutting costs, with about $30 million in annualized savings expected. The plan includes a 9% headcount reduction and should be largely complete by year-end. Migration-related revenue pressure remains a key issue as Health Catalyst adjusts its DOS-to-Ignite transition strategy and revisits at-risk ARR. The company now expects $260 million to $265 million in 2026 revenue and introduced a new bookings target of $22 million to $26 million for the year. Health-Tech Revival: 3 Stocks Set for a Big 2025 Rebound Health Catalyst (NASDAQ:HCAT) reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company’s operating model, reducing costs and shifting the business further toward technology-led growth. Chief Executive Officer Ben Albert said the company is moving with urgency after a review of its cost structure, product portfolio, go-to-market model, organizational design and client delivery approach. He said the review reinforced the strength of Health Catalyst’s assets but also showed that the company’s prior operating structure had become “fragmented and cumbersome.” → Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum The 10 Top-Rated Stocks by Wall Street Analysts in June 2021 “We are pleased to report a strong first quarter with solid bookings and results that exceeded expectations on both revenue and adjusted EBITDA,” Albert said. He added that Health Catalyst ended the quarter in a strong cash position and is making progress toward “durable and efficient growth.” Chief Financial Officer Jason Alger said total revenue for the first quarter ended March 31 was $70.8 million, above the company’s guided range of $68 million to $70 million. Technology revenue was $49.5 million, while professional services revenue was $21.3 million. → 3 Ways to Target the Resources Powering AI and Data Centers Alger said the revenue trajectory is beginning to reflect pressure tied to the company’s prior migration strateg...

Investor releaseQuarter not tagged2026-05-12

Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics

Zacks

For the quarter ended March 2026, Health Catalyst (HCAT) reported revenue of $70.76 million, down 10.9% over the same period last year. EPS came in at $0.02, compared to $0.01 in the year-ago quarter. The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $69.34 million. With the consensus EPS estimate being $0.01, the EPS surprise was +300%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Professional services: $21.29 million versus the three-analyst average estimate of $19.93 million. The reported number represents a year-over-year change of -23.8%. Revenue- Technology: $49.47 million versus $49.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.9% change. Adjusted Gross Profit- Professional Services: $4.14 million compared to the $3.34 million average estimate based on three analysts. Adjusted Gross Profit- Technology: $32.3 million versus the three-analyst average estimate of $32.74 million. View all Key Company Metrics for Health Catalyst here>>> Shares of Health Catalyst have returned +52.6% over the past month versus the Zacks S&P 500 composite's +9.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Health Catalyst, Inc. (HCAT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Investor releaseQuarter not tagged2026-05-12

Health Catalyst Inc (HCAT) Q1 2026 Earnings Call Highlights: Surpassing Expectations with ...

GuruFocus.com

This article first appeared on GuruFocus. Total Revenue: $70.8 million for Q1 2026, exceeding the guided range of $68 million to $70 million. Technology Revenue: $49.5 million for Q1 2026. Professional Services Revenue: $21.3 million for Q1 2026. Adjusted Gross Margin: 51.5% for Q1 2026, compared to 49.2% in the prior year period. Adjusted Technology Gross Margin: 55.3% for Q1 2026. Adjusted Professional Services Gross Margin: 19.4% for Q1 2026. Adjusted Operating Expenses: $27.3 million, representing 39% of revenue for Q1 2026. Adjusted EBITDA: $9.1 million for Q1 2026, exceeding the guided range of $7 million to $8 million. Adjusted Net Income Per Share: $0.02 with a weighted average share count of 72.6 million. Cash, Cash Equivalents, and Short-term Investments: $108.8 million as of the end of Q1 2026, reflecting a $13.1 million increase from December 31, 2025. Annual Run Rate Cost Savings from Project NEXUS: Approximately $30 million expected. Full Year 2026 Revenue Guidance: $260 million to $265 million. Full Year 2026 Adjusted EBITDA Guidance: $30 million to $33 million. Q2 2026 Revenue Guidance: $68 million to $70 million. Q2 2026 Adjusted EBITDA Guidance: $9 million to $10 million. New Bookings for 2026: Expected $22 million to $26 million. Warning! GuruFocus has detected 3 Warning Signs with HCAT. Is HCAT fairly valued? Test your thesis with our free DCF calculator. Release Date: May 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Health Catalyst Inc (NASDAQ:HCAT) reported strong first-quarter results, exceeding expectations on both revenue and adjusted EBITDA. The company ended the quarter with a strong cash position, reflecting a $13.1 million increase in cash, cash equivalents, and short-term investments compared to December 31, 2025. Project NEXUS, a comprehensive operational and business restructuring initiative, is expected to generate annual run rate cost savings of approximately $30 million. The introduction of total bookings as a simplified operating metric provides a clear benchmark of success and aligns with investor feedback. Health Catalyst Inc (NASDAQ:HCAT) is focusing on AI initiatives, leveraging 18 years of proprietary healthcare improvement data to enhance its competitive advantage. The company is experiencing revenue pressure due to its previous migration strategy, whic...

Investor releaseQuarter not tagged2026-05-12

Health Catalyst: Q1 Earnings Snapshot

Associated Press

SOUTH JORDAN, Utah (AP) — SOUTH JORDAN, Utah (AP) — Health Catalyst Inc. (HCAT) on Monday reported a loss of $111 million in its first quarter. On a per-share basis, the South Jordan, Utah-based company said it had a loss of $1.53. Earnings, adjusted for asset impairment costs and amortization costs, were 2 cents per share. The provider of data analytics for the health care industry posted revenue of $70.8 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $69.3 million. For the current quarter ending in June, Health Catalyst said it expects revenue in the range of $68 million to $70 million. The company expects full-year revenue in the range of $260 million to $265 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HCAT at https://www.zacks.com/ap/HCAT

Investor releaseQuarter not tagged2026-05-12

Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates

Zacks

Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +300.00%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Health Catalyst, which belongs to the Zacks Medical Info Systems industry, posted revenues of $70.76 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.04%. This compares to year-ago revenues of $79.41 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Health Catalyst shares have lost about 36.4% since the beginning of the year versus the S&P 500's gain of 8.1%. While Health Catalyst has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Health Catalyst was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future....

Investor releaseQuarter not tagged2026-05-12

Health Catalyst (HCAT) Q1 2026 Earnings Transcript

Motley Fool

Image source: The Motley Fool. Monday, May 11, 2026 at 5 p.m. ET Chief Executive Officer — Ben Albert Chief Financial Officer — Jason Alger Finance and Investor Relations Senior Vice President — Stephanie St. Clair Stephanie St. Clair: Good afternoon, and welcome to the Health Catalyst, Inc. earnings call for the first quarter of 2026, which ended on 03/31/2026. My name is Stephanie St. Clair, Finance and Investor Relations Senior Vice President. With me on the call today are Ben Albert, our Chief Executive Officer, and Jason Alger, Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today, as well as in our related Form 8-Ks furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. As a reminder, today’s call is being recorded and a replay will be available following the conclusion of the call. During today’s call, we will make forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our future growth, financial outlook for the second quarter and full year 2026, market conditions, AI initiatives, bookings, retention, operational priorities, strategic and restructuring initiatives, client migrations, and the general anticipated performance of our business. These forward-looking statements are based on management’s current views and expectations as of today and should not be relied upon as representing our views of any subsequent date. We disclaim any obligation to update any forward-looking statements or outlook. Actual results may materially differ. Please refer to the risk factors in our most recent Form 10-K for the full year 2025 filed with the SEC on 03/12/2026, and our Form 10-Q for 2026 filed today. We will also refer to certain non-GAAP financial measures to provide additional information to investors. Non-GAAP financial information is presented for supplemental purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation of our non-GAAP financial measures to their most comparable GAAP measures is provided in our press release. We will provide forward-looking guidance for certain non-GAAP financial measures in this earnings call an...

Investor releaseQuarter not tagged2026-05-12

Health Catalyst Reports First Quarter 2026 Results

GlobeNewswire

SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026. “We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health Catalyst. “More importantly, this quarter we took the first decisive step toward transforming our operating model and aligning the company around its highest-conviction technology opportunities. This is not a short-term cost exercise. It is a strategic reset designed to build a more focused, durable Health Catalyst capable of meeting the opportunity in front of us. I am confident in the leadership team and board we have assembled to build the intelligence-driven technology company healthcare needs.” Financial Highlights for the Three Months Ended March 31, 2026 Key Financial Measures ________________________ (1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP. Financial Outlook Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure. For the second quarter of 2026, we expect: Total revenue of $68 million to $70 million, and Adjusted EBITDA of $9 million to $10 million. For the full year of 2026, we expect: Total revenue of $260 million to $265 million, and Adjusted EBITDA of $30 million to $33 million. We have not provided forward-looking guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted. Quarterly Conference Call Details We will host a conference call to review the results today, Wednesday, May 11, 2026, at 5:00 p.m. E.T. The conference call can be accessed by dial...

TranscriptFY2026 Q12026-05-11

FY2026 Q1 earnings call transcript

Earnings source - 59 paragraphs
Operator

Would now like to turn the call over to Stephanie St. Clair, Senior Vice President of Finance and Investor Relations.

Stephanie St. Clair

Good afternoon, welcome to Health Catalyst earnings call for the first quarter of 2026, which ended March 31, 2026. My name is Stephanie St. Clair, Finance and Investor Relations Senior Vice President. With me on the call today are Ben Albert, our Chief Executive Officer, and Jason Alger, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today, as well as in our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. As a reminder, today's call is being recorded and a replay will be available following the conclusion of the call.

Stephanie St. Clair

During today's call, we will make forward-looking statements pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 regarding our future growth, financial outlook for the second quarter and full year 2026, market conditions, AI initiatives, bookings, retention, operational priorities, strategic and restructuring initiatives, client migrations, and the general anticipated performance of our business. These forward-looking statements are based on management's current views and expectations as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statements or outlook. Actual results may materially differ. Please refer to the risk factors in our most recent Form 10-K for the full year 2025 filed with the SEC on March 12, 2026, and our Form 10-Q for the first quarter of 2026 filed today.

Stephanie St. Clair

We will also refer to certain non-GAAP financial measures to provide additional information to investors. Non-GAAP financial information is presented for supplemental purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation of our non-GAAP financial measures to their most comparable GAAP measures is provided in our press release. We will provide forward-looking guidance for certain non-GAAP financial measures in this earnings call and are not providing the comparable GAAP measures and therefore have not provided reconciliations because there are items that may impact the comparable GAAP measures that are not within our control. With that, I'll turn the call over to Ben.

Ben Albert

Thank you, Stephanie, thank you to everyone for joining us today. We are pleased to report a strong first quarter with solid bookings and results that exceeded expectations on both revenue and adjusted EBITDA. We ended the quarter in a strong cash position and combined with the cost savings from streamlining our operations, we are making progress as we position the company for durable and efficient growth. We are also introducing a new performance metric that we believe provides a clear benchmark of success and issuing full-year guidance as promised. Jason will detail our performance and outlook in his remarks. First, I'd like to spend a few minutes sharing learnings from our initial assessment and the actions we've taken and will continue to take with urgency to transform the company's operating model, simplify our organizational structure, and align resources around our highest conviction technology opportunities.

Ben Albert

Over the last few months, we have begun examining every dimension of the business, from our cost structure and our product portfolio to our go-to-market approach, organizational design, leadership, technology infrastructure, and how we deliver value to clients. This review has reinforced both the strength of our foundation and the need to operate differently. One of the most significant findings from that review was the direct connection between our previous migration strategy and the revenue pressure we are managing this year. Setting a rigid timeline for DOS to Ignite migration efforts over the last two years has created a churn dynamic, which is heavily impacting 2026. It is the area we have addressed most aggressively, prioritizing client success and retention to build a more durable revenue base.

Ben Albert

As we shared in our March earnings call, we stopped managing the migrations as a one-size-fits-all program and conducted a line-by-line review of every remaining client. We developed a tailored plan for each client's specific situation and have strengthened the teams dedicated to taking clients through this process, including options where clients stay on DOS for an extended period of time. The initial review is now complete and gives us a new level of visibility into a path forward. As we look at our business holistically, we believe that Health Catalyst has exceptional core assets, including 18 years of proprietary healthcare improvement data, deep client relationships, proven outcomes, and a team that genuinely cares about improving healthcare. However, these assets were hampered by a fragmented and cumbersome business structure that created friction and lacked focus for clients and teammates.

Ben Albert

While this accumulated complexity will take time to unwind and will create short-term revenue pressure, we are focused and confident in our plan of action. Ultimately, we believe this short-term impact is necessary to achieve more profitable growth long term. Importantly, we are building a leadership team that is equipped and eager to execute this plan. We've added significant experience across nearly every function, bringing in operators with vision, executional discipline, and a track record of results. We also recently promoted our new Chief Marketing Officer, who is already transforming our messaging, product positioning, and how to take our solutions to market. Our new Chief Growth Officer, who is bringing her excitement and data-driven leadership to our growth function. At the board level, we've also made significant changes.

Ben Albert

We recently welcomed Steve Nelson, who currently serves as the President of Aetna and brings deep healthcare expertise and public company leadership experience. He previously served as Chief Executive Officer of UnitedHealthcare, ChenMed, and Duly Health and Care, building and scaling delivery models where health outcomes, provider experience, cost discipline, clinical performance, and consumer engagement operate as a single integrated strategy. Out of our seven current board members, he is one of four board members who have joined in the last year, including a new chair. The board refresh brings fresh perspective, outside expertise, and strategic insight. Moving forward, our focus is building a technology business that wins in the market, operating with efficiency and discipline and investing in our Ignite Intelligence that differentiates our solutions. Two weeks ago, we announced a comprehensive operational and business restructuring we're calling Project Nexus.

Ben Albert

It is a strategic initiative designed to fundamentally transform our operating model, improve our cost structure, and advance each of these priorities. This initiative is expected to generate annual run rate cost savings of approximately $30 million and accelerate the progress we've already made to integrate our core functions and consolidate our operations under one company with one commercial approach, one client-facing team, and one set of standards. On the engineering side, we piloted a new development model utilizing highly efficient pods and proprietary AI development agents. In initial pilots, development teams increased story points delivered by as much as 100% per developer, allowing us to simultaneously reshape our cost structure and accelerate product innovation. Finally, we are introducing total bookings as a simplified operating metric. We consider investor feedback carefully and believe it is one of the most direct indicators of whether our commercial engine is working.

Ben Albert

Combined with our guidance and continued to focus on adjusted technology gross margin and cash generation, we believe our metrics will give you a clear and consistent framework to track the success of this transformation. Now let me tell you how the work we are doing positions us for the opportunity ahead and why I took this job. Healthcare is at an inflection point. The finance margins, shifting payer mix, rising labor costs is structural, not cyclical. In this environment, organizations are looking for more than incrementally better tools. They are looking for a partner who can help them reduce costs, improve clinical quality, and grow consumer relationships while delivering meaningful outcomes. That is the market we are built for, and AI strengthens our ability to serve it. Healthcare data infrastructure has increasingly commoditized.

Ben Albert

Durable advantage lives in the intelligence built on top of it, and our advantage rests on something no one else has: our wealth of improvement data, the link between an intervention, its cost, and its measured outcome. 18 years and thousands of improvement engagements later, our proprietary data set compounds, building our competitive advantage. A new entrant cannot manufacture this data set retrospectively. These engagements include an evidence base that tells us what reduces costs, improves clinical quality, and grows consumer engagement, and then can be calibrated to each system's case mix, cost structure, workforce, and starting point. The result is a prescriptive roadmap that identifies opportunities sized in dollars and interventions ranked by impact, sequenced so the foundations are in place before the harder work begins. That is the foundation of our AI strategy.

Ben Albert

We are building a growing suite of agentic AI models across cost management, clinical quality, consumer experience, and ambulatory growth embedded in our domain-specific applications. These improvement agents will combine multiple layers of machine learning models and LLMs to surface the right opportunities for each health system, quantify the impact, and guide execution. We are building a moat by combining our depth of improvement data with purpose-built AI agents at scale. Work that once required months of consulting services and manual effort is being embedded in our technology solution and recalculates daily as conditions change, improving with every outcome delivered. I want to add something more personal. I believe that a thriving health system is foundational, as essential as education, as central to the fabric of community as any institution we have. For the communities they serve, health systems provide care, they provide employment, and they provide resilience.

Ben Albert

When they struggle, communities feel it in ways that go far beyond healthcare. That reality is under threat today, and many communities do not yet see it coming. Health Catalyst exists to help health systems sustain and strengthen that role. Our improvement data is the foundation, and AI will allow us to make that expertise efficient, scalable, and accessible to every system that needs it. That is the company we are building. In conclusion, we asked for time, and we used it to conduct a thorough assessment of the business. We are acting on what we found. We are transforming the company's operating model by simplifying our organizational structure and aligning resources around our highest conviction technology opportunities. We have increased visibility into the DOS to Ignite migration impact, and we expect that the majority of that revenue pressure will be absorbed in 2026.

Ben Albert

These changes to our operating model position us better 2027 with a more efficient organization and a commercial engine that will be aligned to where we believe we will win. With that, I'll turn it over to Jason.

Jason Alger

Thanks, Ben. I wanna start by putting the Q1 results in context, then describe the transformation we are undertaking and the framework we are using to measure it. The financials this quarter reflect the very early stages of that work. We exceeded our guidance on both revenue and adjusted EBITDA. We're reporting strong Q1 bookings, which gives us confidence our commercial simplification work is gaining traction, and our cost discipline continues to show up in the numbers. Let me walk through the details. For the first quarter of 2026, total revenue was $70.8 million, exceeding the high end of our guided range of $68 million-$70 million. Technology revenue was $49.5 million, and professional services revenue was $21.3 million. On the top line, I would point to a few things.

Jason Alger

Our revenue trajectory is beginning to show some of the revenue pressure that Ben discussed. It was partially offset by milestone delivery-based revenue and new client revenue. Professional services revenue continues to decline as expected as we shift toward a more technology-led model, which is by design. Adjusted gross margin for the first quarter was 51.5% compared to 49.2% in the prior year period. Adjusted technology gross margin was 65.3%, and adjusted professional services gross margin was 19.4%. Adjusted technology gross margin reflects duplicate hosting costs as we migrate clients to Ignite and heavy data loading costs associated with HIE client deployments before revenue can be recognized. We are laser-focused on margin expansion as part of the transformation to streamline delivery and optimize our cost structure.

Jason Alger

We expect that the operational changes that Ben described, which includes certain headcount and non-headcount changes that impact cost of revenue, will begin to show up in Q2 results and will become more evident in the second half of 2026. Adjusted operating expenses in Q1 were $27.3 million, representing 39% of revenue, compared to $32.8 million or 41% of revenue in Q1 2025. We have been disciplined about cost management while protecting investments in areas that directly support the transformation. Adjusted EBITDA for the first quarter was $9.1 million, exceeding the high end of our guided range of $7 million-$8 million, compared to $6.3 million in Q1 2025. Adjusted net income per share was $0.02, with a weighted average share count of 72.6 million.

Jason Alger

Turning to the balance sheet, we ended the quarter with approximately $108.8 million of cash equivalents, and short-term investments. As Ben noted, cash generation is a central focus. This Q1 cash equivalents, and short-term investments value reflects a $13.1 million increase compared to December 31, 2025. Although we don't anticipate this level of cash generation every quarter, we are managing liquidity carefully, and we expect the restructuring actions we are taking will meaningfully improve our ability to generate cash. Let me walk through the math of Project Nexus, because I think it is important for investors to see how these actions connect to the financial trajectory we are targeting. We expect total second quarter restructuring charges of approximately $4 million. This program spans workforce actions, infrastructure consolidation, and go-to-market realignment.

Jason Alger

We expect the majority of these charges to be incurred in Q2, with the restructuring substantially complete by year-end. Project Nexus is expected to generate annualized run rate savings of approximately $30 million, inclusive of direct savings of approximately $22 million from the 9% reduction in headcount and reductions in non-headcount spend, such as infrastructure, subscriptions, and contractors, and indirect savings of approximately $8 million from the closing of open headcount and cancellation of other previously planned expenses. It is important to note that these savings are annualized, so not all of the benefit will be seen in 2026. As we think about 2026, we expect our quarterly adjusted operating expenses to decrease by $3 million-$4 million compared to Q1. We also expect our quarterly adjusted cost of revenue to decrease by $1 million-$2 million.

Jason Alger

These quarterly impacts will start to take effect in Q2 and will ramp throughout the year. We are making meaningful structural changes to how this company operates and what it costs to run. Today, we are providing full year 2026 guidance. I wanna walk through not just the numbers, but how we expect the year to unfold, because the shape of the year matters as much as the totals. The full year 2026, we currently expect total revenue of $260 million-$265 million, adjusted EBITDA of $30 million-$33 million. For Q2 2026, we currently expect total revenue of $68 million-$70 million, adjusted EBITDA of $9 million-$10 million.

Jason Alger

Our full year revenue guidance reflects the weight of short-term revenue pressure related to the previous migration strategy, as well as the TAMS and professional services related revenue reductions and the assessment that Ben described. The churn that we are working through today is largely the result of prior decisions that force clients into an accelerated decision point on the migration before we had the right retention program and client-facing structure in place. On our previous earnings call, we shared certain data points related to the DOS to Ignite migration, including the $12.5 million of ARR notified down sell churn and approximately $52 million of potentially at-risk ARR. Following the client-by-client review, we anticipate retaining at least $22 million of the previously identified $52 million of at-risk ARR.

Jason Alger

This leaves approximately $30 million of at-risk ARR, which we are focused on retaining through dedicated account plans tailored to each client's needs. The current expected impact will be approximately $20 million in 2026 and $10 million in 2027. For simplicity, we've provided this detail in a chart in our earnings release. We would note that a number of clients will continue to use our application solutions going forward, even after transitioning to their own infrastructure. As we previously noted, the migration impact is temporary, and we expect to be generally through the strains of the migration at the end of 2027. This does not mean every migration is complete as we are extending the availability of DOS, but it means we will transition each client when the time is right on what products make sense.

Jason Alger

Additionally, the changes we have put in place are helping us to build a more durable revenue base exiting 2027. As we prioritize a mix shift to higher margin technology revenue, we continue to work with clients on the right services approach. In certain cases, it makes sense for clients to insource team members, which aligns with our technology-led strategy and improves our margin profile. Our best estimate today is that exiting 2026, our services segment will be between $55 million-$65 million in revenue annually. Our Q1 bookings were strong and our pipeline supports moderate bookings in Q2 and positive bookings momentum in the second half. Over the course of 2026, we expect $22 million-$26 million in new bookings, which includes all ARR and non-recurring revenue.

Jason Alger

We use new bookings as an operating metric and define it further in our Form 10-Q filed today. We will report results for this new metric on an annual basis. We aim to turn bookings into revenue promptly for the advantage of our clients and our business. From an adjusted gross margin standpoint, we expect adjusted technology gross margin to fluctuate modestly quarter to quarter and to finish the year in the mid-60s. Technology margin expansion is a key focus area of our business moving forward, but it will take time to realize improvement in our financials given duplicate costs from the Ignite migrations and heavy data loading costs associated with HIE client deployments.

Jason Alger

We anticipate that our adjusted professional services gross margin will decline over the course of the year as we continue to work through the migrations with a full year margin expectation in the mid to low teens. We are targeting adjusted EBITDA that reflects changes to the operating model taking hold. This is the financial case for why the short term migration-related revenue pain is worth it. We believe our new structure will allow us to lean into high priority opportunities and realize improving leverage when growth returns. We are managing this business for durable value creation and believe the actions we are taking in 2026 are laying the foundation for that. With that, I'll turn the call back to Ben.

Ben Albert

Thanks, Jason. In closing, I wanna thank our clients for their continued partnership and our team members for their commitment during this period of progress and transition. We are energized by the transformation underway, and our board and management team are fully aligned on driving shareholder value. We have a clear plan and are executing with urgency and discipline. We remain confident in the direction of the business and in our ability to create long-term value for our clients and shareholders. Operator, we are now ready to take questions.

Operator

The floor is now open for questions. At this time, if you have a question or comment, press star one on your telephone keypad. If at any point your question is answered, you may remove yourself from the queue by pressing star two. Again, we kindly ask that you limit yourself to one question and that you pick up your handset when posing your questions to provide optimal sound quality. Thank you. Our first question is coming from Stan Berenshteyn with Wells Fargo. Please go ahead. Your line is open.

Stan Berenshteyn

Hi. Thanks for taking my questions. On the prepared remarks, you mentioned a bigger focus on the technology business. Are there any value-added services that are still part of this vision, or is the expectation here that services is going to shrink as a mix of total revenue? Thank you.

Ben Albert

Thank you for the question. The expectation is that services will shrink as we go forward as in terms of as a percentage of revenue as we invest in technology-driven opportunities for the company overall. We certainly see and will continue to see areas of opportunity for our services in the business. An area of example is a chart abstraction. While we might infuse more AI into the process of our chart abstraction work, we will still have wraparound services to meet our clients where they are. Sometimes that will require utilizing some services in the business, but we will see a mix shift as we go forward, especially with the AI strategy we're unfolding and how we're really taking advantage of the highest technology opportunities the business has.

Stan Berenshteyn

Great. Thank you.

Operator

Thank you. We'll now move on to John Pinney with Canaccord Genuity. Please go ahead. Your line is open.

John Pinney

Hi. Yeah, John Pinney on for Richard Close. Thanks for the questions. I guess I just wanted to get greater detail on. You said, like, the shift from DOS to Ignite was kind of a sticking point, is trying to force that shift onto people. I guess, like, what is the hesitation of people shifting? Is it just, like, the flux that it would create during that shift? Is there something about DOS that they wanna stick with that Ignite doesn't have?

Ben Albert

Thanks for the question. There are a couple things we can answer that with, DOS provides a lot of value to our clients, and our clients have invested a lot in DOS over time. Taking on that transition to a new platform, whether it be Ignite or other, is just a lot of work, and it requires a tremendous amount of effort. They get tremendous value from DOS today. For many clients, they're excited to stay on DOS, and over time, they may move over to Ignite. We wanna just be able to meet them where they are and support them through that transition as we go forward. DOS does provide a lot of value, and I think that's what we're seeing.

Ben Albert

Now, as it relates to the second part of the question, you know, the data platform level has been commoditized a bit, and the value really is in the intelligence that sits on top of the data platform. We've got this 18 years of proprietary improvement data that sits on top of the data platform, and this is on top of Ignite, of course, that we're enabling these AI capabilities off of across these three really critical areas of helping our clients manage costs, helping them improve the consumer engagement and growth from the ambulatory side of the business, and also driving clinical quality. As we invest in AI and use that improvement layer that sits on top of the data platform, we will see more and more take advantage of what Ignite has to offer.

Operator

Thank you. We'll move on now to Jeff Garro with Stephens. Your line is open.

Jeff Garro

Yeah, good afternoon. Thanks for taking the question. Wanna ask about feedback so far on Ignite Intelligence. Curious, what are you hearing from customers in terms of kind of overall budgeting for AI? Feedback on your offering versus efforts or investigations they might have into building it themselves or buying from someone else. Thanks.

Ben Albert

Sure. Thanks, Jeff. The feedback has been really positive as it relates to the initial rollout of our AI capabilities, particular in the cost management side of the equation. We're just very early innings there, the feedback has been excellent, we continue to invest more and more in that work to unearth these capabilities that we can provide. As we talk about what differentiates us and how it really drives measurable improvement for our clients, that's really all about that 18 years of proprietary intelligence that we have on top of the data. That improvement data is what we call it.

Ben Albert

18 years of projects, thousands of projects to help improve our clients across their how they better manage their costs, how they better manage their labor, how they better manage their clinical quality, and how they better manage their consumer experience. We have that data, and we can enable our clients to utilize that with our AI agents that really will make our solutions much more robust and help them manage the changes going forward. There's a lot of excitement, and we believe that will be a huge component of our future growth.

Operator

Thank you. We'll now move on to Jessica Tassan with Piper Sandler. Your line is open. Please go ahead.

Jessica Tassan

Hi, guys. Thanks for taking the question, and appreciate you reinstating the guide. I kind of have a multipart question. Are you able to disclose how many DOS and Ignite customers you have today, and what is the average ARR for DOS customers in 2026 versus Ignite customers in 2026? Just when you say data infrastructure is commoditized, I guess when did that occur? Who are the competitors on the data infrastructure side, and how much of the DOS or Ignite ARR would you ascribe to data infrastructure versus the intelligence layer? Thanks.

Jason Alger

Hey, Jess. Really appreciate the question. I mean, what we have provided in the prepared remarks as well as in the earnings release document is full detail around what we expect from a downsell and churn perspective. We don't have a logo count that we'll be disclosing at this point in time, but we'll keep everyone apprised of how we're projecting there. It does continue to still be less common for an enterprise client to exit entirely. What we are saying is that clients are generally continuing, even if we do see that downsell or churn on the data infrastructure side, they are continuing to maintain those application relationships with us.

Ben Albert

I would just add to the fact you mentioned when did the data platform become commoditized. I think as we talked on prior calls and indicated that the folks like Databricks coming in and Snowflake and cross-industry tech vendors who are working to really enable that data platform layer, but they lack the intelligence that sits on top. They're building the infrastructure layer to support these organizations, and that's happening at times. We can still do the whole thing for clients who need that. Ultimately, what we do now is we have that intelligence layer that can sit on top of that data platform. That Ignite Intelligence can enable our clients and future clients with a much greater improvement opportunity through the intelligence we provide.

Operator

Thank you. We'll now move on to Aidan Conniff with Stifel. Your line is open.

Aidan Conniff

Hi, all. Thanks for taking my question. I have a two-parter. First, in the $30 million of anticipated churn and down sell, is that entirely the data infrastructure layer? Secondly, thanks for providing the bookings metrics. How quickly are you expecting those to then convert to revenue?

Jason Alger

Hey, Aidan. Appreciate the question. Yeah, related to the $30 million in anticipated churn or down sell, I would say it's heavily focused on the data infrastructure side. It's not 100% data infrastructure. We are seeing some of that churn come out of the application side as well. Primarily focused more on data infrastructure. Then to the second part of that question. I'm sorry, could you repeat that second part, Aidan? Apologize.

Aidan Conniff

Yeah. Just in terms of the bookings you guys provided, how are you thinking about those then converting to revenue in terms of the timeframe, we should see them appear?

Jason Alger

Got it. Yeah, appreciate you repeating. We would expect bookings to convert into revenue. Typically, it takes about three to six months for those bookings to convert into revenue. It really does depend on the project or on the technology that we're deploying, but that would be most common, would be three to six months.

Operator

Thank you. We'll move on to Daniel Grosslight with Citi. Your line is open. Please go ahead.

Daniel Grosslight

Hey, thanks for taking the question. This is the response of Daniel. I know you mentioned earlier in the call that your pipeline supports moderate bookings in 2Q and positive momentum. Does this positive momentum represent, like, a change in behavior among potential clients relative to your initial expectations, or would you characterize those behavior overall steady and there's still a little bit hesitant hesitancy in the market? Thanks.

Ben Albert

I think it can be attributed to, just our approach. I mean, we recently added a new head of marketing. We've got a new chief growth officer, and we're really focused on how we are taking our platform and our capabilities to market and how we're messaging those solutions in market so people understand exactly what it is that we do as an organization. Health systems are still making purchases today, but the bar is definitely higher. The ROI threshold is higher. They don't want just one solution. They want a partner who can provide multiple solutions like we can across cost intelligence, labor intelligence or clinical intelligence, consumer intelligence.

Ben Albert

When you can come to them with a message of how well we understand you as a 18 years in healthcare with tremendous improvement data that sits on top of it, and then the ability to convert that data into meaningful outcomes and measurable improvement for them across multiple areas of their business, that capability is truly unique and differentiated in the market, and we do anticipate that driving the back half of the year.

Daniel Grosslight

Understood. Thank you.

Operator

Thank you. Once again, if you would like to ask a question, please press star one now on your telephone keypad. We'll move next to Ryan Daniels with William Blair. Your line is open.

Ryan Daniels

Yeah, thanks for taking the question, all the color thus far. Ben, one for you. I just wanted to dig into the DOS-related ARR churn and potential buy down. Can you talk a little bit more about the $52 million and what actually delineates the $22 million you anticipate to retain versus the $30 million? What are the characteristics defining your ability to retain some of that ARR versus the potential risk? Then, you know, what are you guys doing to mitigate that risk going forward, or is it just likely gone at this point given some of the conversion structures already in place? Thanks.

Ben Albert

Thanks for the question. We are working hard to retain as much of that as we can. As we did our assessment over the last really few months, we went line by line against every DOS to Ignite migration account and put a plan together to support them. We're not gonna lose them all. Some will down sell as opposed to full churn obviously. Ultimately, we do have an approach, and we are hopeful to make some inroads there. We just wanna make sure, you know, we're communicating clearly, we're building credibility and making sure that we're setting the right expectations in the market. We do have a plan to go and try and retain as much of that revenue as we can through those account-by-account approaches.

Operator

Thank you. There are no further questions at this time. I'm happy to turn the floor back over to Ben Albert for additional or closing remarks.

Ben Albert

I'd like to thank everybody for joining us today. I think we're super excited about what Health Catalyst can become as we go forward. We're very focused right now on the fundamentals, the launch of Project Nexus to transform our operating model and drive our company forward. We're investing in the areas that we believe will drive growth for our organization. We're trying to provide as much transparency as we possibly can so you can all really understand where our business is and where our business is going. We recognize that our performance hasn't been where we want it, and that we're gonna be judged by the performance that we create here, and we're very focused on executing against that. Thank you all very much for joining us today. Appreciate it.

Operator

Thank you. This concludes today's Health Catalyst first quarter 2026 earnings conference call. Please disconnect your line at this time and have a wonderful day.

Investor releaseQuarter not tagged2026-05-07

Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks

Analysts on Wall Street project that Health Catalyst (HCAT) will announce quarterly earnings of $0.01 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $69.34 million, declining 12.7% from the same quarter last year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. In light of this perspective, let's dive into the average estimates of certain Health Catalyst metrics that are commonly tracked and forecasted by Wall Street analysts. Based on the collective assessment of analysts, 'Revenue- Professional services' should arrive at $19.93 million. The estimate suggests a change of -28.7% year over year. The consensus among analysts is that 'Revenue- Technology' will reach $49.51 million. The estimate suggests a change of -3.8% year over year. Analysts forecast 'Adjusted Gross Profit- Professional Services' to reach $3.34 million. The estimate is in contrast to the year-ago figure of $4.44 million. Analysts expect 'Adjusted Gross Profit- Technology' to come in at $32.74 million. The estimate compares to the year-ago value of $34.61 million. View all Key Company Metrics for Health Catalyst here>>> Over the past month, Health Catalyst shares have recorded returns of +52.4% versus the Zacks S&P 500 composite's +11.4% change. Based on its Zacks Rank #4 (Sell), HCAT will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this fr...

Investor releaseQuarter not tagged2026-05-07

Privia Health (PRVA) Misses Q1 Earnings Estimates

Zacks

Privia Health (PRVA) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -76.19%. A quarter ago, it was expected that this physician practice management company would post earnings of $0.04 per share when it actually produced earnings of $0.07, delivering a surprise of +75%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Privia Health, which belongs to the Zacks Medical Info Systems industry, posted revenues of $603.85 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 7.84%. This compares to year-ago revenues of $480.1 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Privia Health shares have added about 1.2% since the beginning of the year versus the S&P 500's gain of 7.6%. While Privia Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Privia Health was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today...

As of 2026-05-30 • Updated weeklySource: Earnings sourceIngestion runbook